(S)-2-{4-[3-chloro-4-(3-fluoro-benzyloxy)-5 phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy methyl}-morpholine-4-carboxylic acid tert-butyl ester | 859205-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (S)-2-{4-[3-chloro-4-(3-fluoro-benzyloxy)-5 phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy methyl}-morpholine-4-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (2S)-2-[[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methoxymethyl]morpholine-4-carboxylate
• CAS: 859205-93-9
• 化学式: C₃₀H₃₃ClFN₅O₅
• 分子量: 598.074
• InChiKey: YGRRRCKFRCEWOA-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  99.4
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (S)-2-{4-[3-chloro-4-(3-fluoro-benzyloxy)-5 phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy methyl}-morpholine-4-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]-[5-(morpholin-2-ylmethoxymethyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl]-amine
  参考文献：
  名称：

  New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases

  摘要：

  Novel C-5 substituted pyrrolotriazines were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition. The lead compound exhibited promising oral efficacy in both EGFR and HER2 driven human tumor xenograft models. It is hypothesized that its C-5 morpholine side chain binds in the ribose phosphate portion of the ATP binding pocket. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.002
• 作为产物：
  描述：

  4-氯-5-甲基吡咯并[2,1-f][1,2,4]三嗪 在 N-溴代丁二酰亚胺(NBS) 、 间氯过氧苯甲酸 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 四氯化碳 、 二氯甲烷 、 甲苯 为溶剂， 反应 0.67h， 生成 (S)-2-{4-[3-chloro-4-(3-fluoro-benzyloxy)-5 phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy methyl}-morpholine-4-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases

  摘要：

  Novel C-5 substituted pyrrolotriazines were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition. The lead compound exhibited promising oral efficacy in both EGFR and HER2 driven human tumor xenograft models. It is hypothesized that its C-5 morpholine side chain binds in the ribose phosphate portion of the ATP binding pocket. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.002

文献信息

• Di-substituted pyrrolotrizine compounds
  申请人：Gavai V. Ashvinikumar

  公开号：US20050197339A1

  公开（公告）日：2005-09-08

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

  本发明提供了式I的化合物及其药用盐。本发明的化合物抑制生长因子受体的酪氨酸激酶活性，如HER1、HER2和HER4，从而使它们在癌症和其他疾病治疗中作为抗增殖剂具有用途。
• DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1699798A2

  公开（公告）日：2006-09-13
• EP1699798A4
  申请人：——

  公开号：EP1699798A4

  公开（公告）日：2009-03-11
• US7064203B2
  申请人：——

  公开号：US7064203B2

  公开（公告）日：2006-06-20
• [EN] D-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS<br/>[FR] COMPOSES DE PYRROLOTRIAZINE DISUBSTITUEE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005065266A2

  公开（公告）日：2005-07-21

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.